KALA BIO holder David Lazar reports 3.9% stake
KALA BIO, Inc. shareholder David E. Lazar filed an amended beneficial ownership report showing he now holds 719,404 shares of KALA common stock, representing 3.9% of the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
KALA BIO, Inc. shareholder David E. Lazar filed an amended beneficial ownership report showing he now holds 719,404 shares of KALA common stock, representing 3.9% of the company. This percentage is based on 18,589,787 shares outstanding as of June 9, 2026.
The filing states that Lazar’s position consists of Conversion Shares received upon converting Series AA Preferred Stock he purchased under a securities purchase agreement, with an aggregate purchase price of $1,308,007. As of April 24, 2026, he ceased to be a beneficial owner of more than 5% of KALA’s outstanding shares.
Key Figures
Key Terms
beneficially owned financial
Series AA Preferred Stock financial
Form S-3/A regulatory
Schedule 13D regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of KALA (KALA) does David E. Lazar currently beneficially own?
AI-generated analysis. How Rhea-AI works. Not financial advice.